261 related articles for article (PubMed ID: 33523504)
1. Inhibition of organic cation transporter 3 activity by tyrosine kinase inhibitors.
Alim K; Moreau A; Bruyère A; Jouan E; Denizot C; Nies AT; Parmentier Y; Fardel O
Fundam Clin Pharmacol; 2021 Oct; 35(5):919-929. PubMed ID: 33523504
[TBL] [Abstract][Full Text] [Related]
2. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.
Minematsu T; Giacomini KM
Mol Cancer Ther; 2011 Mar; 10(3):531-9. PubMed ID: 21252289
[TBL] [Abstract][Full Text] [Related]
3. Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1.
Omote S; Matsuoka N; Arakawa H; Nakanishi T; Tamai I
Sci Rep; 2018 Jun; 8(1):9237. PubMed ID: 29915248
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action.
Zhu HJ; Appel DI; Gründemann D; Richelson E; Markowitz JS
Pharmacol Res; 2012 Apr; 65(4):491-6. PubMed ID: 22342816
[TBL] [Abstract][Full Text] [Related]
5. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
6. High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3.
Chen EC; Matsson P; Azimi M; Zhou X; Handin N; Yee SW; Artursson P; Giacomini KM
Pharm Res; 2022 Jul; 39(7):1599-1613. PubMed ID: 35089508
[TBL] [Abstract][Full Text] [Related]
7. Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors.
Duan H; Hu T; Foti RS; Pan Y; Swaan PW; Wang J
Drug Metab Dispos; 2015 Nov; 43(11):1773-80. PubMed ID: 26285765
[TBL] [Abstract][Full Text] [Related]
8. The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3.
Massmann V; Edemir B; Schlatter E; Al-Monajjed R; Harrach S; Klassen P; Holle SK; Sindic A; Dobrivojevic M; Pavenstädt H; Ciarimboli G
Pflugers Arch; 2014 Mar; 466(3):517-27. PubMed ID: 23982114
[TBL] [Abstract][Full Text] [Related]
9. Interaction of organic cation transporter 3 (SLC22A3) and amphetamine.
Zhu HJ; Appel DI; Gründemann D; Markowitz JS
J Neurochem; 2010 Jul; 114(1):142-9. PubMed ID: 20402963
[TBL] [Abstract][Full Text] [Related]
10. Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors.
Jouan E; Moreau A; Bruyere A; Alim K; Denizot C; Parmentier Y; Fardel O
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):625-635. PubMed ID: 34275128
[TBL] [Abstract][Full Text] [Related]
11. Interaction of ALK Inhibitors with Polyspecific Organic Cation Transporters and the Impact of Substrate-Dependent Inhibition on the Prediction of Drug-Drug Interactions.
Tsang YP; López Quiñones AJ; Vieira LS; Wang J
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765282
[TBL] [Abstract][Full Text] [Related]
12. Novel compound, organic cation transporter 3 detection agent and organic cation transporter 3 activity inhibitor, WO2015002150 A1: a patent evaluation.
Hu T; Wang L; Pan X; Qi H
Expert Opin Ther Pat; 2016 Aug; 26(8):857-60. PubMed ID: 27097290
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
Nies AT; Hofmann U; Resch C; Schaeffeler E; Rius M; Schwab M
PLoS One; 2011; 6(7):e22163. PubMed ID: 21779389
[TBL] [Abstract][Full Text] [Related]
14. Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization.
Solbach TF; Grube M; Fromm MF; Zolk O
J Cardiovasc Pharmacol; 2011 Oct; 58(4):409-17. PubMed ID: 21697722
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines.
Sayyed K; Camillerapp C; Le Vée M; Bruyère A; Nies AT; Abdel-Razzak Z; Fardel O
Toxicol In Vitro; 2019 Feb; 54():10-22. PubMed ID: 30189235
[TBL] [Abstract][Full Text] [Related]
16. Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors.
Herraez E; Al-Abdulla R; Soto M; Briz O; Bettinger D; Bantel H; Del Carmen S; Serrano MA; Geier A; Marin JJG; Macias RIR
Biochem Pharmacol; 2023 Nov; 217():115812. PubMed ID: 37722628
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.
Khurana V; Minocha M; Pal D; Mitra AK
Drug Metabol Drug Interact; 2014; 29(4):249-59. PubMed ID: 24807167
[TBL] [Abstract][Full Text] [Related]
18. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
19. Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220.
Mayati A; Bruyere A; Moreau A; Jouan E; Denizot C; Parmentier Y; Fardel O
PLoS One; 2015; 10(12):e0144667. PubMed ID: 26657401
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Hirota T; Muraki S; Ieiri I
Clin Pharmacokinet; 2019 Apr; 58(4):403-420. PubMed ID: 29915924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
